PMID- 7545835
OWN - NLM
STAT- MEDLINE
DCOM- 19951017
LR  - 20190819
IS  - 0300-483X (Print)
IS  - 0300-483X (Linking)
VI  - 101
IP  - 3
DP  - 1995 Aug 25
TI  - The tolerability and pharmacology of interleukin-6 administered in combination 
      with GM-CSF or G-CSF in the rhesus monkey.
PG  - 157-66
AB  - The tolerability and potential target organ toxicity of rhIL-6 administered 
      subcutaneously (s.c.) with rhGM-CSF or rhG-CSF were investigated in healthy 
      nonhuman primates. Fifteen Rhesus monkeys were randomized to receive one of the 
      following five regimens: rhIL-6, rhGM-CSF, rhG-CSF, rhIL-6 and rhGM-CSF, or 
      rhIL-6 and rhG-CSF. Each cytokine was administered s.c. once daily at 20 
      micrograms/kg/day for 30-31 days. Marked increases in blood leukocyte counts 
      (predominantly neutrophils) were observed in the rhGM-CSF and rhG-CSF treatment 
      groups, but only a mild trend toward increased WBCs was observed with rhIL-6 
      alone. Platelet counts increased 1.7- to 2.2-fold in the rhIL-6 and rhGM-CSF 
      groups. All regimens were well tolerated. RhIL-6, alone or in combination with 
      either CSF, had no significant toxic effects at the dosages tested. Minimal to 
      moderate bone marrow hyperplasia was observed in all except rhIL-6-treated 
      animals, which correlated well with peripheral blood increases in WBCs. 
      RhIL-6-treated animals demonstrated increased fibrinogen concentrations and 
      erythrocyte sedimentation rates, decreased serum albumin/globulin ratios, and 
      increased serum alpha-2-macroglobulin concentrations. Increased synthesis of 
      acute-phase proteins was not observed in the other groups. Combining rhIL-6 with 
      rhGM-CSF or rhG-CSF may reduce the rhIL-6-mediated acute-phase response while 
      maintaining the desirable hematopoietic effects of the stimulating factors.
FAU - Myers, L A
AU  - Myers LA
AD  - Department of Drug Safety, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 
      07936, USA.
FAU - Boyce, J T
AU  - Boyce JT
FAU - Robison, R L
AU  - Robison RL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Ireland
TA  - Toxicology
JT  - Toxicology
JID - 0361055
RN  - 0 (Drug Combinations)
RN  - 0 (Interleukin-6)
RN  - 0 (Serum Albumin)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Blood/*drug effects
MH  - Blood Sedimentation/drug effects
MH  - Drug Combinations
MH  - Drug Evaluation, Preclinical
MH  - Granulocyte Colony-Stimulating Factor/*administration & dosage
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/*administration & dosage
MH  - Injections, Subcutaneous
MH  - Interleukin-6/administration & dosage/*toxicity
MH  - Macaca mulatta
MH  - Male
MH  - Random Allocation
MH  - Serum Albumin/drug effects
EDAT- 1995/08/25 00:00
MHDA- 1995/08/25 00:01
CRDT- 1995/08/25 00:00
PHST- 1995/08/25 00:00 [pubmed]
PHST- 1995/08/25 00:01 [medline]
PHST- 1995/08/25 00:00 [entrez]
AID - 0300483X9503081P [pii]
AID - 10.1016/0300-483x(95)03081-p [doi]
PST - ppublish
SO  - Toxicology. 1995 Aug 25;101(3):157-66. doi: 10.1016/0300-483x(95)03081-p.